Treatment	B:C0087111
for	O
Rheumatoid	O
Arthritis	I:C0003873
and	O
Risk	O
of	O
Alzheimer	O
's	I:C0002395
Disease	I:C0002395
:	O
A	O
Nested	O
Case	I:C0027775
-	I:C0027775
Control	I:C0027775
Analysis	I:C0027775
.	O

Treatment	O
for	O
Rheumatoid	B:C0003873
Arthritis	I:C0003873
and	O
Risk	O
of	O
Alzheimer	O
's	I:C0002395
Disease	I:C0002395
:	O
A	O
Nested	O
Case	I:C0027775
-	I:C0027775
Control	I:C0027775
Analysis	I:C0027775
.	O

Treatment	O
for	O
Rheumatoid	O
Arthritis	I:C0003873
and	O
Risk	B:C1281905
of	O
Alzheimer	O
's	I:C0002395
Disease	I:C0002395
:	O
A	O
Nested	O
Case	I:C0027775
-	I:C0027775
Control	I:C0027775
Analysis	I:C0027775
.	O

Treatment	O
for	O
Rheumatoid	O
Arthritis	I:C0003873
and	O
Risk	O
of	O
Alzheimer	B:C0002395
's	I:C0002395
Disease	I:C0002395
:	O
A	O
Nested	O
Case	I:C0027775
-	I:C0027775
Control	I:C0027775
Analysis	I:C0027775
.	O

Treatment	O
for	O
Rheumatoid	O
Arthritis	I:C0003873
and	O
Risk	O
of	O
Alzheimer	O
's	I:C0002395
Disease	I:C0002395
:	O
A	O
Nested	B:C0027775
Case	I:C0027775
-	I:C0027775
Control	I:C0027775
Analysis	I:C0027775
.	O

It	O
is	O
increasingly	O
becoming	O
accepted	O
that	O
inflammation	B:C0021368
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
,	O
as	O
several	O
immune	O
-	O
related	O
genes	O
have	O
been	O
associated	O
with	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
.	O

It	O
is	O
increasingly	O
becoming	O
accepted	O
that	O
inflammation	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B:C0699748
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
,	O
as	O
several	O
immune	O
-	O
related	O
genes	O
have	O
been	O
associated	O
with	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
.	O

It	O
is	O
increasingly	O
becoming	O
accepted	O
that	O
inflammation	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
,	O
as	O
several	O
immune	O
-	O
related	O
genes	O
have	O
been	O
associated	O
with	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
.	O

It	O
is	O
increasingly	O
becoming	O
accepted	O
that	O
inflammation	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
)	O
,	O
as	O
several	O
immune	O
-	O
related	O
genes	O
have	O
been	O
associated	O
with	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
.	O

It	O
is	O
increasingly	O
becoming	O
accepted	O
that	O
inflammation	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
,	O
as	O
several	O
immune	B:C0020962
-	O
related	O
genes	O
have	O
been	O
associated	O
with	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
.	O

It	O
is	O
increasingly	O
becoming	O
accepted	O
that	O
inflammation	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
,	O
as	O
several	O
immune	O
-	O
related	O
genes	B:C0017337
have	O
been	O
associated	O
with	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
.	O

It	O
is	O
increasingly	O
becoming	O
accepted	O
that	O
inflammation	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
,	O
as	O
several	O
immune	O
-	O
related	O
genes	O
have	O
been	O
associated	O
with	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
.	O

Among	O
these	O
is	O
tumor	B:C1456820
necrosis	I:C1456820
factor	I:C1456820
(	I:C1456820
TNF	I:C1456820
)	I:C1456820
-α	I:C1456820
,	O
a	O
proinflammatory	O
cytokine	I:C0079189
known	O
to	O
play	O
an	O
important	O
role	O
in	O
autoimmune	O
disorders	I:C0004364
,	O
including	O
rheumatoid	O
arthritis	I:C0003873
(	O
rheumatoid	O
arthritis	I:C0003873
)	O
.	O

Among	O
these	O
is	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
(	I:C1456820
TNF	I:C1456820
)	I:C1456820
-α	I:C1456820
,	O
a	O
proinflammatory	B:C0079189
cytokine	I:C0079189
known	O
to	O
play	O
an	O
important	O
role	O
in	O
autoimmune	O
disorders	I:C0004364
,	O
including	O
rheumatoid	O
arthritis	I:C0003873
(	O
rheumatoid	O
arthritis	I:C0003873
)	O
.	O

Among	O
these	O
is	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
(	I:C1456820
TNF	I:C1456820
)	I:C1456820
-α	I:C1456820
,	O
a	O
proinflammatory	O
cytokine	I:C0079189
known	O
to	O
play	O
an	O
important	O
role	O
in	O
autoimmune	B:C0004364
disorders	I:C0004364
,	O
including	O
rheumatoid	O
arthritis	I:C0003873
(	O
rheumatoid	O
arthritis	I:C0003873
)	O
.	O

Among	O
these	O
is	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
(	I:C1456820
TNF	I:C1456820
)	I:C1456820
-α	I:C1456820
,	O
a	O
proinflammatory	O
cytokine	I:C0079189
known	O
to	O
play	O
an	O
important	O
role	O
in	O
autoimmune	O
disorders	I:C0004364
,	O
including	O
rheumatoid	B:C0003873
arthritis	I:C0003873
(	O
rheumatoid	O
arthritis	I:C0003873
)	O
.	O

Among	O
these	O
is	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
(	I:C1456820
TNF	I:C1456820
)	I:C1456820
-α	I:C1456820
,	O
a	O
proinflammatory	O
cytokine	I:C0079189
known	O
to	O
play	O
an	O
important	O
role	O
in	O
autoimmune	O
disorders	I:C0004364
,	O
including	O
rheumatoid	O
arthritis	I:C0003873
(	O
rheumatoid	B:C0003873
arthritis	I:C0003873
)	O
.	O

Although	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	O
arthritis	I:C0003873
appear	O
to	O
involve	O
similar	O
pathological	O
mechanisms	I:C0030660
through	O
the	O
production	O
of	O
TNF-α	O
,	I:C1456820
the	O
relationship	O
between	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	O
arthritis	I:C0003873
remains	O
unknown	O
.	O

Although	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	B:C0003873
arthritis	I:C0003873
appear	O
to	O
involve	O
similar	O
pathological	O
mechanisms	I:C0030660
through	O
the	O
production	O
of	O
TNF-α	O
,	I:C1456820
the	O
relationship	O
between	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	O
arthritis	I:C0003873
remains	O
unknown	O
.	O

Although	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	O
arthritis	I:C0003873
appear	O
to	O
involve	O
similar	O
pathological	B:C0030660
mechanisms	I:C0030660
through	O
the	O
production	O
of	O
TNF-α	O
,	I:C1456820
the	O
relationship	O
between	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	O
arthritis	I:C0003873
remains	O
unknown	O
.	O

Although	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	O
arthritis	I:C0003873
appear	O
to	O
involve	O
similar	O
pathological	O
mechanisms	I:C0030660
through	O
the	O
production	B:C0003261
of	O
TNF-α	O
,	I:C1456820
the	O
relationship	O
between	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	O
arthritis	I:C0003873
remains	O
unknown	O
.	O

Although	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	O
arthritis	I:C0003873
appear	O
to	O
involve	O
similar	O
pathological	O
mechanisms	I:C0030660
through	O
the	O
production	O
of	O
TNF-α	B:C1456820
,	I:C1456820
the	O
relationship	O
between	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	O
arthritis	I:C0003873
remains	O
unknown	O
.	O

Although	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	O
arthritis	I:C0003873
appear	O
to	O
involve	O
similar	O
pathological	O
mechanisms	I:C0030660
through	O
the	O
production	O
of	O
TNF-α	O
,	I:C1456820
the	O
relationship	O
between	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	O
arthritis	I:C0003873
remains	O
unknown	O
.	O

Although	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	O
arthritis	I:C0003873
appear	O
to	O
involve	O
similar	O
pathological	O
mechanisms	I:C0030660
through	O
the	O
production	O
of	O
TNF-α	O
,	I:C1456820
the	O
relationship	O
between	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
and	O
rheumatoid	B:C0003873
arthritis	I:C0003873
remains	O
unknown	O
.	O

To	O
determine	O
the	O
relative	O
risk	O
of	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
and	O
non-	O
rheumatoid	O
arthritis	I:C0003873
patients	O
,	O
and	O
whether	O
anti-TNF	O
therapy	I:C0281481
for	O
rheumatoid	O
arthritis	I:C0003873
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
in	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

To	O
determine	O
the	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	B:C0003873
arthritis	I:C0003873
patients	O
and	O
non-	O
rheumatoid	O
arthritis	I:C0003873
patients	O
,	O
and	O
whether	O
anti-TNF	O
therapy	I:C0281481
for	O
rheumatoid	O
arthritis	I:C0003873
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
in	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

To	O
determine	O
the	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
and	O
non-	O
rheumatoid	B:C0003873
arthritis	I:C0003873
patients	O
,	O
and	O
whether	O
anti-TNF	O
therapy	I:C0281481
for	O
rheumatoid	O
arthritis	I:C0003873
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
in	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

To	O
determine	O
the	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
and	O
non-	O
rheumatoid	O
arthritis	I:C0003873
patients	O
,	O
and	O
whether	O
anti-TNF	B:C0281481
therapy	I:C0281481
for	O
rheumatoid	O
arthritis	I:C0003873
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
in	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

To	O
determine	O
the	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
and	O
non-	O
rheumatoid	O
arthritis	I:C0003873
patients	O
,	O
and	O
whether	O
anti-TNF	O
therapy	I:C0281481
for	O
rheumatoid	B:C0003873
arthritis	I:C0003873
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
in	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

To	O
determine	O
the	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
and	O
non-	O
rheumatoid	O
arthritis	I:C0003873
patients	O
,	O
and	O
whether	O
anti-TNF	O
therapy	I:C0281481
for	O
rheumatoid	O
arthritis	I:C0003873
was	O
associated	O
with	O
a	O
lower	O
risk	B:C1281905
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
in	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

To	O
determine	O
the	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
and	O
non-	O
rheumatoid	O
arthritis	I:C0003873
patients	O
,	O
and	O
whether	O
anti-TNF	O
therapy	I:C0281481
for	O
rheumatoid	O
arthritis	I:C0003873
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
in	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

To	O
determine	O
the	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
and	O
non-	O
rheumatoid	O
arthritis	I:C0003873
patients	O
,	O
and	O
whether	O
anti-TNF	O
therapy	I:C0281481
for	O
rheumatoid	O
arthritis	I:C0003873
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
in	O
rheumatoid	B:C0003873
arthritis	I:C0003873
patients	O
.	O

We	O
performed	O
a	O
nested	B:C0027775
case	I:C0027775
-	I:C0027775
control	I:C0027775
study	I:C0027775
of	O
more	O
than	O
8.5	O
million	O
commercially	O
insured	O
adults	O
(	O
aged	O
≥	O
18	O
years	O
)	O
in	O
all	O
50	O
US	O
states	I:C0041703
,	O
Puerto	O
Rico	I:C0034044
,	O
and	O
US	O
Virgin	I:C0042752
Islands	I:C0042752
in	O
the	O
Verisk	O
Health	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

We	O
performed	O
a	O
nested	O
case	I:C0027775
-	I:C0027775
control	I:C0027775
study	I:C0027775
of	O
more	O
than	O
8.5	O
million	O
commercially	O
insured	O
adults	O
(	O
aged	O
≥	O
18	O
years	O
)	O
in	O
all	O
50	O
US	B:C0041703
states	I:C0041703
,	O
Puerto	O
Rico	I:C0034044
,	O
and	O
US	O
Virgin	I:C0042752
Islands	I:C0042752
in	O
the	O
Verisk	O
Health	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

We	O
performed	O
a	O
nested	O
case	I:C0027775
-	I:C0027775
control	I:C0027775
study	I:C0027775
of	O
more	O
than	O
8.5	O
million	O
commercially	O
insured	O
adults	O
(	O
aged	O
≥	O
18	O
years	O
)	O
in	O
all	O
50	O
US	O
states	I:C0041703
,	O
Puerto	B:C0034044
Rico	I:C0034044
,	O
and	O
US	O
Virgin	I:C0042752
Islands	I:C0042752
in	O
the	O
Verisk	O
Health	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

We	O
performed	O
a	O
nested	O
case	I:C0027775
-	I:C0027775
control	I:C0027775
study	I:C0027775
of	O
more	O
than	O
8.5	O
million	O
commercially	O
insured	O
adults	O
(	O
aged	O
≥	O
18	O
years	O
)	O
in	O
all	O
50	O
US	O
states	I:C0041703
,	O
Puerto	O
Rico	I:C0034044
,	O
and	O
US	B:C0042752
Virgin	I:C0042752
Islands	I:C0042752
in	O
the	O
Verisk	O
Health	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

We	O
performed	O
a	O
nested	O
case	I:C0027775
-	I:C0027775
control	I:C0027775
study	I:C0027775
of	O
more	O
than	O
8.5	O
million	O
commercially	O
insured	O
adults	O
(	O
aged	O
≥	O
18	O
years	O
)	O
in	O
all	O
50	O
US	O
states	I:C0041703
,	O
Puerto	O
Rico	I:C0034044
,	O
and	O
US	O
Virgin	I:C0042752
Islands	I:C0042752
in	O
the	O
Verisk	B:C0242356
Health	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

We	O
derived	O
a	O
sub-cohort	B:C0599755
of	O
subjects	O
with	O
a	O
diagnosis	O
of	O
rheumatoid	O
arthritis	I:C0003873
(	O
controls	O
)	O
,	O
or	O
rheumatoid	O
arthritis	I:C0003873
and	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
cases	O
)	O
,	O
matching	O
cases	O
and	O
controls	O
based	O
on	O
age	O
,	O
sex	O
,	O
exposure	O
assessment	O
period	O
,	O
and	O
methotrexate	O
treatment	O
.	O

We	O
derived	O
a	O
sub-cohort	O
of	O
subjects	O
with	O
a	O
diagnosis	B:C0011900
of	O
rheumatoid	O
arthritis	I:C0003873
(	O
controls	O
)	O
,	O
or	O
rheumatoid	O
arthritis	I:C0003873
and	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
cases	O
)	O
,	O
matching	O
cases	O
and	O
controls	O
based	O
on	O
age	O
,	O
sex	O
,	O
exposure	O
assessment	O
period	O
,	O
and	O
methotrexate	O
treatment	O
.	O

We	O
derived	O
a	O
sub-cohort	O
of	O
subjects	O
with	O
a	O
diagnosis	O
of	O
rheumatoid	B:C0003873
arthritis	I:C0003873
(	O
controls	O
)	O
,	O
or	O
rheumatoid	O
arthritis	I:C0003873
and	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
cases	O
)	O
,	O
matching	O
cases	O
and	O
controls	O
based	O
on	O
age	O
,	O
sex	O
,	O
exposure	O
assessment	O
period	O
,	O
and	O
methotrexate	O
treatment	O
.	O

We	O
derived	O
a	O
sub-cohort	O
of	O
subjects	O
with	O
a	O
diagnosis	O
of	O
rheumatoid	O
arthritis	I:C0003873
(	O
controls	O
)	O
,	O
or	O
rheumatoid	B:C0003873
arthritis	I:C0003873
and	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
cases	O
)	O
,	O
matching	O
cases	O
and	O
controls	O
based	O
on	O
age	O
,	O
sex	O
,	O
exposure	O
assessment	O
period	O
,	O
and	O
methotrexate	O
treatment	O
.	O

We	O
derived	O
a	O
sub-cohort	O
of	O
subjects	O
with	O
a	O
diagnosis	O
of	O
rheumatoid	O
arthritis	I:C0003873
(	O
controls	O
)	O
,	O
or	O
rheumatoid	O
arthritis	I:C0003873
and	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
(	O
cases	O
)	O
,	O
matching	O
cases	O
and	O
controls	O
based	O
on	O
age	O
,	O
sex	O
,	O
exposure	O
assessment	O
period	O
,	O
and	O
methotrexate	O
treatment	O
.	O

We	O
derived	O
a	O
sub-cohort	O
of	O
subjects	O
with	O
a	O
diagnosis	O
of	O
rheumatoid	O
arthritis	I:C0003873
(	O
controls	O
)	O
,	O
or	O
rheumatoid	O
arthritis	I:C0003873
and	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
cases	O
)	O
,	O
matching	B:C0150103
cases	O
and	O
controls	O
based	O
on	O
age	O
,	O
sex	O
,	O
exposure	O
assessment	O
period	O
,	O
and	O
methotrexate	O
treatment	O
.	O

We	O
also	O
assessed	B:C0086930
relative	I:C0086930
risk	I:C0086930
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
following	O
exposure	O
to	O
standard	O
rheumatoid	O
arthritis	I:C0003873
therapies	O
,	O
including	O
anti-TNF	O
agents	I:C1562242
(	O
infliximab	O
,	O
adalimumab	O
,	O
etanercept	O
)	O
,	O
methotrexate	O
,	O
prednisone	O
,	O
sulfasalazine	O
,	O
and	O
rituximab	O
.	O

We	O
also	O
assessed	O
relative	I:C0086930
risk	I:C0086930
of	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
following	O
exposure	O
to	O
standard	O
rheumatoid	O
arthritis	I:C0003873
therapies	O
,	O
including	O
anti-TNF	O
agents	I:C1562242
(	O
infliximab	O
,	O
adalimumab	O
,	O
etanercept	O
)	O
,	O
methotrexate	O
,	O
prednisone	O
,	O
sulfasalazine	O
,	O
and	O
rituximab	O
.	O

We	O
also	O
assessed	O
relative	I:C0086930
risk	I:C0086930
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
following	O
exposure	O
to	O
standard	O
rheumatoid	B:C0003873
arthritis	I:C0003873
therapies	O
,	O
including	O
anti-TNF	O
agents	I:C1562242
(	O
infliximab	O
,	O
adalimumab	O
,	O
etanercept	O
)	O
,	O
methotrexate	O
,	O
prednisone	O
,	O
sulfasalazine	O
,	O
and	O
rituximab	O
.	O

We	O
also	O
assessed	O
relative	I:C0086930
risk	I:C0086930
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
following	O
exposure	O
to	O
standard	O
rheumatoid	O
arthritis	I:C0003873
therapies	B:C0087111
,	O
including	O
anti-TNF	O
agents	I:C1562242
(	O
infliximab	O
,	O
adalimumab	O
,	O
etanercept	O
)	O
,	O
methotrexate	O
,	O
prednisone	O
,	O
sulfasalazine	O
,	O
and	O
rituximab	O
.	O

We	O
also	O
assessed	O
relative	I:C0086930
risk	I:C0086930
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
following	O
exposure	O
to	O
standard	O
rheumatoid	O
arthritis	I:C0003873
therapies	O
,	O
including	O
anti-TNF	B:C1562242
agents	I:C1562242
(	O
infliximab	O
,	O
adalimumab	O
,	O
etanercept	O
)	O
,	O
methotrexate	O
,	O
prednisone	O
,	O
sulfasalazine	O
,	O
and	O
rituximab	O
.	O

We	O
also	O
assessed	O
relative	I:C0086930
risk	I:C0086930
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
following	O
exposure	O
to	O
standard	O
rheumatoid	O
arthritis	I:C0003873
therapies	O
,	O
including	O
anti-TNF	O
agents	I:C1562242
(	O
infliximab	B:C0666743
,	O
adalimumab	O
,	O
etanercept	O
)	O
,	O
methotrexate	O
,	O
prednisone	O
,	O
sulfasalazine	O
,	O
and	O
rituximab	O
.	O

We	O
also	O
assessed	O
relative	I:C0086930
risk	I:C0086930
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
following	O
exposure	O
to	O
standard	O
rheumatoid	O
arthritis	I:C0003873
therapies	O
,	O
including	O
anti-TNF	O
agents	I:C1562242
(	O
infliximab	O
,	O
adalimumab	B:C1122087
,	O
etanercept	O
)	O
,	O
methotrexate	O
,	O
prednisone	O
,	O
sulfasalazine	O
,	O
and	O
rituximab	O
.	O

We	O
also	O
assessed	O
relative	I:C0086930
risk	I:C0086930
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
following	O
exposure	O
to	O
standard	O
rheumatoid	O
arthritis	I:C0003873
therapies	O
,	O
including	O
anti-TNF	O
agents	I:C1562242
(	O
infliximab	O
,	O
adalimumab	O
,	O
etanercept	B:C0717758
)	O
,	O
methotrexate	O
,	O
prednisone	O
,	O
sulfasalazine	O
,	O
and	O
rituximab	O
.	O

We	O
also	O
assessed	O
relative	I:C0086930
risk	I:C0086930
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
following	O
exposure	O
to	O
standard	O
rheumatoid	O
arthritis	I:C0003873
therapies	O
,	O
including	O
anti-TNF	O
agents	I:C1562242
(	O
infliximab	O
,	O
adalimumab	O
,	O
etanercept	O
)	O
,	O
methotrexate	B:C0025677
,	O
prednisone	O
,	O
sulfasalazine	O
,	O
and	O
rituximab	O
.	O

We	O
also	O
assessed	O
relative	I:C0086930
risk	I:C0086930
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
following	O
exposure	O
to	O
standard	O
rheumatoid	O
arthritis	I:C0003873
therapies	O
,	O
including	O
anti-TNF	O
agents	I:C1562242
(	O
infliximab	O
,	O
adalimumab	O
,	O
etanercept	O
)	O
,	O
methotrexate	O
,	O
prednisone	B:C0032952
,	O
sulfasalazine	O
,	O
and	O
rituximab	O
.	O

We	O
also	O
assessed	O
relative	I:C0086930
risk	I:C0086930
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
following	O
exposure	O
to	O
standard	O
rheumatoid	O
arthritis	I:C0003873
therapies	O
,	O
including	O
anti-TNF	O
agents	I:C1562242
(	O
infliximab	O
,	O
adalimumab	O
,	O
etanercept	O
)	O
,	O
methotrexate	O
,	O
prednisone	O
,	O
sulfasalazine	B:C0036078
,	O
and	O
rituximab	O
.	O

We	O
also	O
assessed	O
relative	I:C0086930
risk	I:C0086930
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
following	O
exposure	O
to	O
standard	O
rheumatoid	O
arthritis	I:C0003873
therapies	O
,	O
including	O
anti-TNF	O
agents	I:C1562242
(	O
infliximab	O
,	O
adalimumab	O
,	O
etanercept	O
)	O
,	O
methotrexate	O
,	O
prednisone	O
,	O
sulfasalazine	O
,	O
and	O
rituximab	B:C0393022
.	O

Odds	O
ratios	O
were	O
adjusted	O
for	O
comorbidities	O
,	O
including	O
coronary	B:C0010068
artery	I:C0010068
disease	I:C0010068
,	O
diabetes	O
mellitus	I:C0011849
,	O
and	O
peripheral	O
vascular	I:C0085096
disease	I:C0085096
.	O

Odds	O
ratios	O
were	O
adjusted	O
for	O
comorbidities	O
,	O
including	O
coronary	O
artery	I:C0010068
disease	I:C0010068
,	O
diabetes	B:C0011849
mellitus	I:C0011849
,	O
and	O
peripheral	O
vascular	I:C0085096
disease	I:C0085096
.	O

Odds	O
ratios	O
were	O
adjusted	O
for	O
comorbidities	O
,	O
including	O
coronary	O
artery	I:C0010068
disease	I:C0010068
,	O
diabetes	O
mellitus	I:C0011849
,	O
and	O
peripheral	B:C0085096
vascular	I:C0085096
disease	I:C0085096
.	O

Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
was	O
more	O
prevalent	O
(	O
p	O
<	O
0.0001	O
)	O
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
(	O
0.79	O
%	O
)	O
than	O
among	O
those	O
without	O
rheumatoid	O
arthritis	I:C0003873
(	O
0.11	O
%	O
)	O
.	O

Alzheimer	O
's	I:C0002395
disease	I:C0002395
was	O
more	O
prevalent	O
(	O
p	O
<	O
0.0001	O
)	O
among	O
rheumatoid	B:C0003873
arthritis	I:C0003873
patients	O
(	O
0.79	O
%	O
)	O
than	O
among	O
those	O
without	O
rheumatoid	O
arthritis	I:C0003873
(	O
0.11	O
%	O
)	O
.	O

Alzheimer	O
's	I:C0002395
disease	I:C0002395
was	O
more	O
prevalent	O
(	O
p	O
<	O
0.0001	O
)	O
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
(	O
0.79	O
%	O
)	O
than	O
among	O
those	O
without	O
rheumatoid	B:C0003873
arthritis	I:C0003873
(	O
0.11	O
%	O
)	O
.	O

Chronic	B:C4315615
conditions	I:C4315615
such	O
as	O
coronary	O
artery	I:C0010068
disease	I:C0010068
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1.48	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.04	O
-2.05	O
;	O
p	O
=	O
0.03	O
)	O
,	O
diabetes	O
(	O
OR	O
1.86	O
;	O
95	O
%	O
CI	O
1.32	O
-	O
2.62	O
;	O
p	O
=	O
0.0004	O
)	O
,	O
and	O
peripheral	O
vascular	I:C0085096
disease	I:C0085096
(	O
OR	O
1.61	O
;	O
95	O
%	O
CI	O
1.06	O
-	O
2.43	O
;	O
p	O
=	O
0.02	O
)	O
significantly	O
increased	O
the	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

Chronic	O
conditions	I:C4315615
such	O
as	O
coronary	B:C0010068
artery	I:C0010068
disease	I:C0010068
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1.48	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.04	O
-2.05	O
;	O
p	O
=	O
0.03	O
)	O
,	O
diabetes	O
(	O
OR	O
1.86	O
;	O
95	O
%	O
CI	O
1.32	O
-	O
2.62	O
;	O
p	O
=	O
0.0004	O
)	O
,	O
and	O
peripheral	O
vascular	I:C0085096
disease	I:C0085096
(	O
OR	O
1.61	O
;	O
95	O
%	O
CI	O
1.06	O
-	O
2.43	O
;	O
p	O
=	O
0.02	O
)	O
significantly	O
increased	O
the	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

Chronic	O
conditions	I:C4315615
such	O
as	O
coronary	O
artery	I:C0010068
disease	I:C0010068
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1.48	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.04	O
-2.05	O
;	O
p	O
=	O
0.03	O
)	O
,	O
diabetes	B:C0011847
(	O
OR	O
1.86	O
;	O
95	O
%	O
CI	O
1.32	O
-	O
2.62	O
;	O
p	O
=	O
0.0004	O
)	O
,	O
and	O
peripheral	O
vascular	I:C0085096
disease	I:C0085096
(	O
OR	O
1.61	O
;	O
95	O
%	O
CI	O
1.06	O
-	O
2.43	O
;	O
p	O
=	O
0.02	O
)	O
significantly	O
increased	O
the	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

Chronic	O
conditions	I:C4315615
such	O
as	O
coronary	O
artery	I:C0010068
disease	I:C0010068
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1.48	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.04	O
-2.05	O
;	O
p	O
=	O
0.03	O
)	O
,	O
diabetes	O
(	O
OR	O
1.86	O
;	O
95	O
%	O
CI	O
1.32	O
-	O
2.62	O
;	O
p	O
=	O
0.0004	O
)	O
,	O
and	O
peripheral	B:C0085096
vascular	I:C0085096
disease	I:C0085096
(	O
OR	O
1.61	O
;	O
95	O
%	O
CI	O
1.06	O
-	O
2.43	O
;	O
p	O
=	O
0.02	O
)	O
significantly	O
increased	O
the	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

Chronic	O
conditions	I:C4315615
such	O
as	O
coronary	O
artery	I:C0010068
disease	I:C0010068
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1.48	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.04	O
-2.05	O
;	O
p	O
=	O
0.03	O
)	O
,	O
diabetes	O
(	O
OR	O
1.86	O
;	O
95	O
%	O
CI	O
1.32	O
-	O
2.62	O
;	O
p	O
=	O
0.0004	O
)	O
,	O
and	O
peripheral	O
vascular	I:C0085096
disease	I:C0085096
(	O
OR	O
1.61	O
;	O
95	O
%	O
CI	O
1.06	O
-	O
2.43	O
;	O
p	O
=	O
0.02	O
)	O
significantly	O
increased	O
the	O
relative	O
risk	O
of	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

Chronic	O
conditions	I:C4315615
such	O
as	O
coronary	O
artery	I:C0010068
disease	I:C0010068
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1.48	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.04	O
-2.05	O
;	O
p	O
=	O
0.03	O
)	O
,	O
diabetes	O
(	O
OR	O
1.86	O
;	O
95	O
%	O
CI	O
1.32	O
-	O
2.62	O
;	O
p	O
=	O
0.0004	O
)	O
,	O
and	O
peripheral	O
vascular	I:C0085096
disease	I:C0085096
(	O
OR	O
1.61	O
;	O
95	O
%	O
CI	O
1.06	O
-	O
2.43	O
;	O
p	O
=	O
0.02	O
)	O
significantly	O
increased	O
the	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	B:C0003873
arthritis	I:C0003873
patients	O
.	O

Exposure	O
to	O
anti-TNF	B:C1562242
agents	I:C1562242
as	O
a	O
class	O
,	O
but	O
not	O
other	O
immunosuppressive	O
drugs	I:C0021081
studied	O
,	O
was	O
associated	O
with	O
lowered	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
(	O
unadjusted	O
OR	O
0.44	O
;	O
95	O
%	O
CI	O
0.22-0.87	O
;	O
p	O
=	O
0.02	O
;	O
adjusted	O
OR	O
0.45	O
;	O
95	O
%	O
CI	O
0.23-0.90	O
;	O
p	O
=	O
0.02	O
)	O
.	O

Exposure	O
to	O
anti-TNF	O
agents	I:C1562242
as	O
a	O
class	O
,	O
but	O
not	O
other	O
immunosuppressive	B:C0021081
drugs	I:C0021081
studied	O
,	O
was	O
associated	O
with	O
lowered	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
(	O
unadjusted	O
OR	O
0.44	O
;	O
95	O
%	O
CI	O
0.22-0.87	O
;	O
p	O
=	O
0.02	O
;	O
adjusted	O
OR	O
0.45	O
;	O
95	O
%	O
CI	O
0.23-0.90	O
;	O
p	O
=	O
0.02	O
)	O
.	O

Exposure	O
to	O
anti-TNF	O
agents	I:C1562242
as	O
a	O
class	O
,	O
but	O
not	O
other	O
immunosuppressive	O
drugs	I:C0021081
studied	O
,	O
was	O
associated	O
with	O
lowered	O
risk	B:C1281905
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
(	O
unadjusted	O
OR	O
0.44	O
;	O
95	O
%	O
CI	O
0.22-0.87	O
;	O
p	O
=	O
0.02	O
;	O
adjusted	O
OR	O
0.45	O
;	O
95	O
%	O
CI	O
0.23-0.90	O
;	O
p	O
=	O
0.02	O
)	O
.	O

Exposure	O
to	O
anti-TNF	O
agents	I:C1562242
as	O
a	O
class	O
,	O
but	O
not	O
other	O
immunosuppressive	O
drugs	I:C0021081
studied	O
,	O
was	O
associated	O
with	O
lowered	O
risk	O
of	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
patients	O
(	O
unadjusted	O
OR	O
0.44	O
;	O
95	O
%	O
CI	O
0.22-0.87	O
;	O
p	O
=	O
0.02	O
;	O
adjusted	O
OR	O
0.45	O
;	O
95	O
%	O
CI	O
0.23-0.90	O
;	O
p	O
=	O
0.02	O
)	O
.	O

Exposure	O
to	O
anti-TNF	O
agents	I:C1562242
as	O
a	O
class	O
,	O
but	O
not	O
other	O
immunosuppressive	O
drugs	I:C0021081
studied	O
,	O
was	O
associated	O
with	O
lowered	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	B:C0003873
arthritis	I:C0003873
patients	O
(	O
unadjusted	O
OR	O
0.44	O
;	O
95	O
%	O
CI	O
0.22-0.87	O
;	O
p	O
=	O
0.02	O
;	O
adjusted	O
OR	O
0.45	O
;	O
95	O
%	O
CI	O
0.23-0.90	O
;	O
p	O
=	O
0.02	O
)	O
.	O

Sub	O
-	O
group	O
analysis	O
demonstrated	O
that	O
of	O
the	O
three	O
anti-TNF	B:C1562242
agents	I:C1562242
studied	O
,	O
only	O
etanercept	O
(	O
unadjusted	O
OR	O
,	O
0.33	O
;	O
95	O
%	O
CI	O
0.08	O
-	O
0.94	O
;	O
p	O
=	O
0.03	O
;	O
adjusted	O
OR	O
0.30	O
;	O
95	O
%	O
CI	O
0.08	O
-	O
0.89	O
;	O
p	O
=	O
0.02	O
)	O
was	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
in	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

Sub	O
-	O
group	O
analysis	O
demonstrated	O
that	O
of	O
the	O
three	O
anti-TNF	O
agents	I:C1562242
studied	O
,	O
only	O
etanercept	B:C0717758
(	O
unadjusted	O
OR	O
,	O
0.33	O
;	O
95	O
%	O
CI	O
0.08	O
-	O
0.94	O
;	O
p	O
=	O
0.03	O
;	O
adjusted	O
OR	O
0.30	O
;	O
95	O
%	O
CI	O
0.08	O
-	O
0.89	O
;	O
p	O
=	O
0.02	O
)	O
was	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
in	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

Sub	O
-	O
group	O
analysis	O
demonstrated	O
that	O
of	O
the	O
three	O
anti-TNF	O
agents	I:C1562242
studied	O
,	O
only	O
etanercept	O
(	O
unadjusted	O
OR	O
,	O
0.33	O
;	O
95	O
%	O
CI	O
0.08	O
-	O
0.94	O
;	O
p	O
=	O
0.03	O
;	O
adjusted	O
OR	O
0.30	O
;	O
95	O
%	O
CI	O
0.08	O
-	O
0.89	O
;	O
p	O
=	O
0.02	O
)	O
was	O
associated	O
with	O
a	O
decreased	O
risk	B:C1281905
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
in	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

Sub	O
-	O
group	O
analysis	O
demonstrated	O
that	O
of	O
the	O
three	O
anti-TNF	O
agents	I:C1562242
studied	O
,	O
only	O
etanercept	O
(	O
unadjusted	O
OR	O
,	O
0.33	O
;	O
95	O
%	O
CI	O
0.08	O
-	O
0.94	O
;	O
p	O
=	O
0.03	O
;	O
adjusted	O
OR	O
0.30	O
;	O
95	O
%	O
CI	O
0.08	O
-	O
0.89	O
;	O
p	O
=	O
0.02	O
)	O
was	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
in	O
rheumatoid	O
arthritis	I:C0003873
patients	O
.	O

Sub	O
-	O
group	O
analysis	O
demonstrated	O
that	O
of	O
the	O
three	O
anti-TNF	O
agents	I:C1562242
studied	O
,	O
only	O
etanercept	O
(	O
unadjusted	O
OR	O
,	O
0.33	O
;	O
95	O
%	O
CI	O
0.08	O
-	O
0.94	O
;	O
p	O
=	O
0.03	O
;	O
adjusted	O
OR	O
0.30	O
;	O
95	O
%	O
CI	O
0.08	O
-	O
0.89	O
;	O
p	O
=	O
0.02	O
)	O
was	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
in	O
rheumatoid	B:C0003873
arthritis	I:C0003873
patients	O
.	O

There	O
is	O
an	O
increased	O
risk	B:C1281905
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
in	O
the	O
studied	O
rheumatoid	O
arthritis	I:C0003873
population	O
.	O

There	O
is	O
an	O
increased	O
risk	O
of	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
in	O
the	O
studied	O
rheumatoid	O
arthritis	I:C0003873
population	O
.	O

There	O
is	O
an	O
increased	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
in	O
the	O
studied	O
rheumatoid	B:C0003873
arthritis	I:C0003873
population	O
.	O

The	O
relative	O
risk	O
of	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
subjects	O
was	O
lowered	O
in	O
those	O
exposed	O
to	O
etanercept	O
.	O

The	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	B:C0003873
arthritis	I:C0003873
subjects	O
was	O
lowered	O
in	O
those	O
exposed	O
to	O
etanercept	O
.	O

The	O
relative	O
risk	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
among	O
rheumatoid	O
arthritis	I:C0003873
subjects	O
was	O
lowered	O
in	O
those	O
exposed	O
to	O
etanercept	B:C0717758
.	O

Anti-TNF	B:C0281481
therapy	I:C0281481
with	O
etanercept	O
shows	O
promise	O
as	O
a	O
potential	O
treatment	O
for	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
.	O

Anti-TNF	O
therapy	I:C0281481
with	O
etanercept	B:C0717758
shows	O
promise	O
as	O
a	O
potential	O
treatment	O
for	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
.	O

Anti-TNF	O
therapy	I:C0281481
with	O
etanercept	O
shows	O
promise	O
as	O
a	O
potential	O
treatment	B:C0087111
for	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
.	O

Anti-TNF	O
therapy	I:C0281481
with	O
etanercept	O
shows	O
promise	O
as	O
a	O
potential	O
treatment	O
for	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
.	O

